Patents by Inventor Lothar Stitz
Lothar Stitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230233662Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: ApplicationFiled: April 12, 2023Publication date: July 27, 2023Applicant: CureVac SEInventors: Karl-Josef KALLEN, Thomas KRAMPS, Margit SCHNEE, Benjamin PETSCH, Lothar STITZ
-
Patent number: 11672856Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: GrantFiled: June 24, 2020Date of Patent: June 13, 2023Assignee: CureVac SEInventors: Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
-
Publication number: 20220288239Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.Type: ApplicationFiled: May 17, 2022Publication date: September 15, 2022Applicant: CureVac AGInventors: Margit SCHNEE, Thomas KRAMPS, Lothar STITZ, Benjamin PETSCH
-
Patent number: 11369694Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.Type: GrantFiled: May 1, 2020Date of Patent: June 28, 2022Assignee: CureVac AGInventors: Margit Schnee, Thomas Kramps, Lothar Stitz, Benjamin Petsch
-
Publication number: 20210030866Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: ApplicationFiled: October 11, 2020Publication date: February 4, 2021Applicant: CureVac AGInventors: Karl-Josef KALLEN, Thomas KRAMPS, Margit SCHNEE, Benjamin PETSCH, Lothar STITZ
-
Publication number: 20210023199Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: ApplicationFiled: October 9, 2020Publication date: January 28, 2021Applicant: CureVac AGInventors: Karl-Josef KALLEN, Thomas KRAMPS, Margit SCHNEE, Benjamin PETSCH, Lothar STITZ
-
Publication number: 20200316189Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: ApplicationFiled: June 24, 2020Publication date: October 8, 2020Applicant: CureVac AGInventors: Karl-Josef KALLEN, Thomas KRAMPS, Margit SCHNEE, Benjamin PETSCH, Lothar STITZ
-
Publication number: 20200268908Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.Type: ApplicationFiled: May 1, 2020Publication date: August 27, 2020Applicant: CureVac AGInventors: Margit SCHNEE, Thomas KRAMPS, Lothar STITZ, Benjamin PETSCH
-
Patent number: 10729761Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: GrantFiled: February 12, 2019Date of Patent: August 4, 2020Assignee: CureVac AGInventors: Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
-
Patent number: 10682426Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.Type: GrantFiled: February 19, 2016Date of Patent: June 16, 2020Assignee: CureVac AGInventors: Margit Schnee, Thomas Kramps, Lothar Stitz, Benjamin Petsch
-
Patent number: 10596252Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: GrantFiled: November 4, 2018Date of Patent: March 24, 2020Assignee: CureVac AGInventors: Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
-
Publication number: 20190167782Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: ApplicationFiled: February 12, 2019Publication date: June 6, 2019Applicant: CureVac AGInventors: Karl-Josef KALLEN, Thomas KRAMPS, Margit SCHNEE, Benjamin PETSCH, Lothar STITZ
-
Publication number: 20190151438Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: ApplicationFiled: January 31, 2019Publication date: May 23, 2019Applicant: CureVac AGInventors: Karl-Josef KALLEN, Thomas KRAMPS, Margit SCHNEE, Benjamin PETSCH, Lothar STITZ
-
Publication number: 20190054164Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: ApplicationFiled: November 4, 2018Publication date: February 21, 2019Applicant: CureVac AGInventors: Karl-Josef KALLEN, Thomas KRAMPS, Margit SCHNEE, Benjamin PETSCH, Lothar STITZ
-
Patent number: 10172935Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: GrantFiled: March 22, 2017Date of Patent: January 8, 2019Assignee: CureVac AGInventors: Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
-
Publication number: 20170266268Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: ApplicationFiled: February 20, 2017Publication date: September 21, 2017Applicant: CureVac AGInventors: Karl-Josef KALLEN, Thomas KRAMPS, Margit SCHNEE, Benjamin PETSCH, Lothar STITZ
-
Publication number: 20170196969Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: ApplicationFiled: March 22, 2017Publication date: July 13, 2017Applicant: CureVac AGInventors: Karl-Josef KALLEN, Thomas KRAMPS, Margit SCHNEE, Benjamin PETSCH, Lothar STITZ
-
Publication number: 20170182150Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: ApplicationFiled: March 7, 2017Publication date: June 29, 2017Applicant: CureVac AGInventors: Karl-Josef KALLEN, Thomas KRAMPS, Margit SCHNEE, Benjamin PETSCH, Lothar STITZ
-
Patent number: 9623095Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: GrantFiled: February 29, 2012Date of Patent: April 18, 2017Assignee: CureVac AGInventors: Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
-
Publication number: 20160166711Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.Type: ApplicationFiled: February 19, 2016Publication date: June 16, 2016Applicant: CureVac AGInventors: Margit SCHNEE, Thomas KRAMPS, Lothar STITZ, Benjamin PETSCH